Search clinical trials for: PF-05230907

Total 1606 results

Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Mexico, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Helios Klinikum Pforzheim

Recruiting

Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair

Right Heart Failure | Tricuspid Regurgitation | Cardiac Remodeling, Ventricular | Cardiac Remodeling, Atrial

Germany
Parkinson's Foundation
Indiana University; The Parkinson Study Group; Fulgent Genetics

Recruiting

Parkinson's Foundation PD GENEration Genetic Registry

Parkinson's Disease

United States, Canada
Center for Biomedical Research, Inc.

Completed

Topical Phytoterpenes for Plantar Fasciitis

Plantar Fasciitis

United States
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Lymphoma | Multiple Myeloma

Japan
Shire

Completed

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis (TURANDOT)

Ulcerative Colitis

United States, France, Spain, Canada, Korea, Republic of, Australia, Germany, New Zealand, Serbia, Belgium, Czechia, Poland, Hungary, Austria, Bulgaria, Israel, Italy, Netherlands, South Africa, Russian Federation, Slovakia
Pfizer

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

United States, Australia, Canada, Czechia, Poland, Hungary, United Kingdom
Pfizer

Terminated

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) (PODO)

Focal Segmental Glomerulosclerosis (FSGS)

United States, Spain, Czechia, Canada, France, Germany, United Kingdom, Poland, Japan, Mexico, Italy, Slovakia
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

Bioavailability and Food Effect Study of Two Formulations of PF-06650833

Healthy

Belgium
Pfizer

Completed

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

Healthy Volunteers

United States
Pfizer

Completed

Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

Healthy

United States
Pfizer

Completed

Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia

Schizophrenia | Schizo-affective Disorder

South Africa
Pfizer

Terminated

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Neoplasms

United States
Pfizer

Completed

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Reduction of Hypertrophic Skin Scarring

United States, Germany, Hungary, Spain
Pfizer

Terminated

A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

United States
Pfizer

Completed

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

Diabetes Mellitus, Type 2

Singapore
Pfizer

Completed

Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Schizophrenia

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Healthy

United States
Pfizer

Completed

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

Healthy

United States
Pfizer

Terminated

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

Healthy

United States
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
Pfizer

Completed

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Systemic Lupus Erythematosus

Spain, United States, Taiwan, Belgium, Czechia, Japan, Hungary, Germany, United Kingdom, China, France, Australia, Bulgaria, Hong Kong, Korea, Republic of, Colombia, Argentina, Canada, Greece, Italy, Mexico, Poland, Portugal, Romania, S... and more
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Recruiting

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Small Cell Lung Cancer (SCLC) | Follicular Lymphoma (FL) | Castration Resistant Prostate Cancer (CRPC)

United States, Spain, Korea, Republic of, Poland, China, Bulgaria, Russian Federation, Japan
University Health Network, Toronto
Pfizer

Completed

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Oral Cavity Cancer

Canada
Pfizer

Completed

Glasdegib Absolute Bioavailability Study

Healthy Volunteer Study

United States
Pfizer

Completed

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation (B1371026)

Healthy Volunteers

United States
Priovant Therapeutics, Inc.

Active, not recruiting

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis (NEPTUNE)

Non-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan Uveitis

United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Obesity

United States, Taiwan, Canada, Japan
Pfizer

Completed

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Canada, United States, Korea, Republic of, Puerto Rico
Pfizer

Completed

A Study Of PF-04449913 In Select Hematologic Malignancies

Hematologic Malignancies

United States, Italy
Pfizer

Completed

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Colorectal Cancer | Pancreatic Cancer | Cachexia | Non-Small-Cell Lung Cancer

United States
NCIC Clinical Trials Group
Pfizer

Completed

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

Canada
Pfizer

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Pfizer

Completed

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Healthy Participants

United States
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Pfizer

Terminated

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Japan, Italy
Pfizer

Terminated

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Neoplasms

United States
Pfizer

Terminated

First in Patient Study for PF-06840003 in Malignant Gliomas

Astrocytoma | Malignant Glioma | Oligodendroglioma

United States
Pfizer

Completed

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus (BUTTERFLY)

Lupus Erythematosus, Systemic

United States, Germany, Taiwan, Hungary, Poland, Colombia, Argentina, Romania, Chile, Puerto Rico, Korea, Republic of, Moldova, Republic of, Peru

Search clinical trials for: PF-05230907

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations